Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1020 and mRNA-1030 Influenza Vaccines in Healthy Adults
NCT05333289Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Countries
- 1
- Sponsor
- Moderna Inc
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Conditions
- seasonal influenza
01
Overview
Phase 2, randomised, single-blind trial of mRNA-1020 and mRNA-1030 in seasonal influenza (8 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Reactions at Day 7, Number of Participants With Unsolicited Adverse Events at Day 28 and 7 more. Started Apr 2022; status: completed.
02
Design
8 arms- Study design
- RandomizedSingle-blind
mRNA-1030 Dose A
mRNA-1030 at Dose Level A
mRNA-1020 Dose A
mRNA-1020 at Dose Level A
mRNA-1030 Dose B
mRNA-1030 at Dose Level B
mRNA-1020 Dose B
mRNA-1020 at Dose Level B
mRNA-1030 Dose C
mRNA-1030 at Dose Level C
mRNA-1020 Dose C
mRNA-1020 at Dose Level C
2 more in the full profile.
03
Who it enrols
Healthy adults aged 18-75 years with a BMI of 18-35 kg/m^2 who have not received a recent influenza vaccine.
04
Endpoints
Primary
Number of Participants With Solicited Local and Systemic Adverse Reactions
Number of Participants With Unsolicited Adverse Events
Number of Participants With Medically-Attended AEs, AESI, AEs Leading to Withdrawal and SAEs
Geometric Mean Titer of Anti-Hemagglutinin Antibodies
Geometric Mean Titer of Anti-Neuraminidase Antibodies
Secondary
GMT of Anti-HA or Anti-NA Antibodies
GMFR of Anti-HA or Anti-NA Antibodies
Beyond the preview
Go deeper on NCT05333289.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333289.